Parathyroid adenoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(Undo revision 1570070 by Anmol Pitliya (talk))
Tag: Undo
Line 4: Line 4:


==Overview==
==Overview==
Majority of parathyroid adenoma are asymptomatic. However, most common presentation of a parathyroid adenoma is [[hypercalcemia]]. So, parathyroid adenoma shall be differentiated from other conditions presenting pimarily as [[hypercalcemia]].


==Differential Diagnosis==
==Differential Diagnosis==
* Majority of parathyroid adenoma are asymptomatic.
 
* However, most common presentation of a parathyroid adenoma is [[hypercalcemia]].
* So, parathyroid adenoma shall be differentiated from other conditions presenting primarily as [[hypercalcemia]].<ref name="MarcocciCetani2011">{{cite journal|last1=Marcocci|first1=Claudio|last2=Cetani|first2=Filomena|title=Primary Hyperparathyroidism|journal=New England Journal of Medicine|volume=365|issue=25|year=2011|pages=2389–2397|issn=0028-4793|doi=10.1056/NEJMcp1106636}}</ref>
* Common conditions presenting as hypercalcemia include:
** Parathyroid adenoma ([[primary hyperparathyroidism]])
** [[Secondary hyperthyroidism]] (long term)
** Tertiary hyperparathyroidism
** [[Familial hypocalceuric hypercalcemia]]
** Hypercalcemia due to malignancy
*** Humoral hypercalcemia of malignancy
*** Osteolytic tumors
*** Production of calcitriol
*** Ectopic parathyroid gland
** Medication induced
*** [[Lithium]]
*** [[Thiazide diuretics]]
** Nutritional
*** Milk alkali syndrome
*** Vitamin D toxicity
** Granulomatous disease
*** [[Sarcoidosis]]
{|
{|
! colspan="9" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Differential diagnosis of parathyroid adenoma on the basis of hypercalcemia}}
! colspan="9" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Differential diagnosis of parathyroid adenoma on the basis of hypercalcemia}}
Line 42: Line 21:
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Other findings}}
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Other findings}}
|-
|-
! colspan="2" style="background: #DCDCDC; text-align: center;" |Parathyroid adenoma ([[Primary hyperparathyroidism]])
! colspan="2" style="background: #DCDCDC; text-align: center;" |Primary hyperparathyroidism (Parathyroid adenoma)
| style="background: #F5F5F5;" |Increase in [[secretion]] of [[parathyroid hormone]] ([[PTH]]) from a primary process in [[parathyroid gland]]. [[Parathyroid hormone]] causes increase in [[serum]] [[calcium]].
| style="background: #F5F5F5;" |Increase in [[secretion]] of [[parathyroid hormone]] ([[PTH]]) from a primary process in [[parathyroid gland]]. [[Parathyroid hormone]] causes increase in [[serum]] [[calcium]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 69: Line 48:
* [[Intraoperative parathyroid hormone]] monitoring
* [[Intraoperative parathyroid hormone]] monitoring
|-
|-
! colspan="2" style="background: #DCDCDC; text-align: center;" |[[Secondary hyperparathyroidism]] (long term)
! colspan="2" style="background: #DCDCDC; text-align: center;" |Secondary hyperparathyroidism
| style="background: #F5F5F5;" |Increase in [[secretion]] of [[parathyroid hormone]] ([[PTH]]) from a secondary process. [[Parathyroid hormone]] causes increase in [[serum]] [[calcium]] after long periods.
| style="background: #F5F5F5;" |Increase in [[secretion]] of [[parathyroid hormone]] ([[PTH]]) from a secondary process. [[Parathyroid hormone]] causes increase in [[serum]] [[calcium]] after long periods.
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 80: Line 59:
| style="background: #F5F5F5; text-align: center;" | --
| style="background: #F5F5F5; text-align: center;" | --
|-
|-
! colspan="2" style="background: #DCDCDC; text-align: center;" |[[Tertiary hyperparathyroidism]]
! colspan="2" style="background: #DCDCDC; text-align: center;" |Tertiary hyperparathyroidism
| style="background: #F5F5F5;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of  elevated [[parathyroid hormone]]. [[Parathyroid hormone]] causes increase in serum calcium.
| style="background: #F5F5F5;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of  elevated [[parathyroid hormone]]. [[Parathyroid hormone]] causes increase in serum calcium.
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 102: Line 81:
* Urinary calcium/creatinine clearance ratio
* Urinary calcium/creatinine clearance ratio
|-
|-
! rowspan="4" style="background: #DCDCDC; text-align: center;" |'''Malignancy'''
! rowspan="4" style="background: #DCDCDC; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref><ref name="pmid15673803">{{cite journal| author=Stewart AF| title=Clinical practice. Hypercalcemia associated with cancer. | journal=N Engl J Med | year= 2005 | volume= 352 | issue= 4 | pages= 373-9 | pmid=15673803 | doi=10.1056/NEJMcp042806 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15673803  }} </ref>
! style="background: #DCDCDC; text-align: center;" |Humoral hypercalcemia of malignancy
! style="background: #DCDCDC; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref><ref name="pmid7085851">{{cite journal| author=Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE et al.| title=Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. | journal=J Clin Endocrinol Metab | year= 1982 | volume= 55 | issue= 2 | pages= 219-27 | pmid=7085851 | doi=10.1210/jcem-55-2-219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7085851  }} </ref>
| style="background: #F5F5F5;" |[[Tumor]] cells secretes [[parathyroid hormone-related protein]] ([[PTHrP]]) which has similar action as [[parathyroid hormone]].
| style="background: #F5F5F5;" |[[Tumor]] cells secretes [[parathyroid hormone-related protein]] ([[PTHrP]]) which has similar action as [[parathyroid hormone]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 119: Line 98:
* [[MRI]]
* [[MRI]]
|-
|-
! style="background: #DCDCDC; text-align: center;" |Osteolytic tumors
! style="background: #DCDCDC; text-align: center;" |Osteolytic tumors<ref name="pmid15084698">{{cite journal| author=Roodman GD| title=Mechanisms of bone metastasis. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 16 | pages= 1655-64 | pmid=15084698 | doi=10.1056/NEJMra030831 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15084698  }} </ref><ref name="pmid8833902">{{cite journal| author=Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF et al.| title=Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. | journal=J Clin Invest | year= 1996 | volume= 98 | issue= 7 | pages= 1544-9 | pmid=8833902 | doi=10.1172/JCI118947 | pmc=507586 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8833902  }} </ref>
| style="background: #F5F5F5;" |[[Multiple myeloma]] produces [[osteolysis]] of [[bones]] causing [[hypercalcemia]]. [[Osteolytic metasteses]] can cause [[bone resorption]] causing [[hypercalcemia]].
| style="background: #F5F5F5;" |[[Multiple myeloma]] produces [[osteolysis]] of [[bones]] causing [[hypercalcemia]]. [[Osteolytic metasteses]] can cause [[bone resorption]] causing [[hypercalcemia]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 135: Line 114:
* [[Serum protein electrophoresis]]
* [[Serum protein electrophoresis]]
|-
|-
! style="background: #DCDCDC; text-align: center;" |Production of calcitirol
! style="background: #DCDCDC; text-align: center;" |Production of calcitirol<ref name="pmid7944070">{{cite journal| author=Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F| title=Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. | journal=Ann Intern Med | year= 1994 | volume= 121 | issue= 9 | pages= 633-40 | pmid=7944070 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7944070  }} </ref>
| style="background: #F5F5F5;" |Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of [[calcitriol]]. [[Calcitriol]] is active form of [[vitamin D]] and causes [[hypercalcemia]].  
| style="background: #F5F5F5;" |Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of [[calcitriol]]. [[Calcitriol]] is active form of [[vitamin D]] and causes [[hypercalcemia]].  
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 147: Line 126:
* [[MRI]]
* [[MRI]]
|-
|-
! style="background: #DCDCDC; text-align: center;" |Ectopic parathyroid hormone
! style="background: #DCDCDC; text-align: center;" |Ectopic parathyroid hormone<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref>
| style="background: #F5F5F5;" |Some tumors leads to [[Ectopia|ectopic]] production of [[parathyroid hormone]].
| style="background: #F5F5F5;" |Some tumors leads to [[Ectopia|ectopic]] production of [[parathyroid hormone]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 161: Line 140:
|-
|-
! rowspan="2" style="background: #DCDCDC; text-align: center;" |'''Medication induced'''
! rowspan="2" style="background: #DCDCDC; text-align: center;" |'''Medication induced'''
! style="background: #DCDCDC; text-align: center;" |Lithium
! style="background: #DCDCDC; text-align: center;" |Lithium<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref>
| style="background: #F5F5F5;" |[[Lithium]] lowers [[Urinary System|urinary]] [[calcium]] and causes [[hypercalcemia]]. [[Lithium]] has been reported to cause an increase in [[parathyroid hormone]] and enlargement if [[parathyroid gland]] after weeks to months of therapy.
| style="background: #F5F5F5;" |[[Lithium]] lowers [[Urinary System|urinary]] [[calcium]] and causes [[hypercalcemia]]. [[Lithium]] has been reported to cause an increase in [[parathyroid hormone]] and enlargement if [[parathyroid gland]] after weeks to months of therapy.
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 172: Line 151:
* [[Lithium]] levels
* [[Lithium]] levels
|-
|-
! style="background: #DCDCDC; text-align: center;" |Thiazide diuretics
! style="background: #DCDCDC; text-align: center;" |Thiazide diuretics<ref name="pmid26751196">{{cite journal| author=Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ et al.| title=Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 3 | pages= 1166-73 | pmid=26751196 | doi=10.1210/jc.2015-3964 | pmc=4803175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26751196  }}</ref>
| style="background: #F5F5F5;" |[[Thiazide diuretics]] lowers [[urinary]] [[calcium]] [[excretion]] and causes [[hypercalcemia]].
| style="background: #F5F5F5;" |[[Thiazide diuretics]] lowers [[urinary]] [[calcium]] [[excretion]] and causes [[hypercalcemia]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 200: Line 179:
* [[Renal function tests]]
* [[Renal function tests]]
|-
|-
! style="background: #DCDCDC; text-align: center;" |Vitamin D toxicity
! style="background: #DCDCDC; text-align: center;" |Vitamin D toxicity<ref name="pmid81205272">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref><ref name="pmid13135472">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref><ref name="pmid8620732">{{cite journal| author=Sharma OP| title=Vitamin D, calcium, and sarcoidosis. | journal=Chest | year= 1996 | volume= 109 | issue= 2 | pages= 535-9 | pmid=8620732 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8620732  }}</ref>
| style="background: #F5F5F5;" |Excess [[vitamin D]] causes increased [[absorption]] of [[calcium]] from [[intestine]] causing [[hypercalcemia]].
| style="background: #F5F5F5;" |Excess [[vitamin D]] causes increased [[absorption]] of [[calcium]] from [[intestine]] causing [[hypercalcemia]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
* History of:
* History of:
** Excess intake [[vitamin D]]
** Excess intake [[vitamin D]]
** Excess milk fortified with [[vitamin D]]
** Excess milk fortified with [[vitamin D]]<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref>
** Topical application of vitamin D analogue [[calcipotriol]]
** Topical application of vitamin D analogue [[calcipotriol]]<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref>
| style="background: #F5F5F5; text-align: center;" | --
| style="background: #F5F5F5; text-align: center;" | --
| style="background: #F5F5F5; text-align: center;" |↑
| style="background: #F5F5F5; text-align: center;" |↑
Line 214: Line 193:
|-
|-
! style="background: #DCDCDC; text-align: center;" |'''Granulomatous disease'''
! style="background: #DCDCDC; text-align: center;" |'''Granulomatous disease'''
! style="background: #DCDCDC; text-align: center;" |Sarcoidosis
! style="background: #DCDCDC; text-align: center;" |Sarcoidosis<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref>
| style="background: #F5F5F5;" |[[Hypercalcemia]] is causes by endogeous production of [[calcitriol]] by disease-activated [[Macrophage|macrophages]].
| style="background: #F5F5F5;" |[[Hypercalcemia]] is causes by endogeous production of [[calcitriol]] by disease-activated [[Macrophage|macrophages]].
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
Line 236: Line 215:


==References==
==References==
<references />

Revision as of 14:05, 29 May 2019

link=https://www.wikidoc.org/index.php/Parathyroid adenoma
link=https://www.wikidoc.org/index.php/Parathyroid adenoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Differential Diagnosis

Differential diagnosis of parathyroid adenoma on the basis of hypercalcemia
Disorder Mechanism of hypercalcemia Clinical features Laboratory findings Imaging & diagnostic modalities
PTH Calcium Phosphate Other findings
Primary hyperparathyroidism (Parathyroid adenoma) Increase in secretion of parathyroid hormone (PTH) from a primary process in parathyroid gland. Parathyroid hormone causes increase in serum calcium.
  • Usually asymptomatic
  • Hypercalcemia detected on routine biochemical panel
 ↑ ↑ ↓/Normal Normal/↑ calcitriol Findings of bone resorption:

Preoperative localization of hyperfunctioning parathyroid gland:

Predicting post-operative success:

Secondary hyperparathyroidism Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes increase in serum calcium after long periods. ↑ ↓/Normal ↑ --
Tertiary hyperparathyroidism Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes increase in serum calcium. ↑ ↑ ↑ --
Familial hypocalciuric hypercalcemia This is a genetic disorder caused my mutation in calcium-sensing receptor gene.
  • A benign condition
  • Does not require treatment
 Normal/↑ Normal/↑ -- --
  • Urinary calcium/creatinine clearance ratio
Malignancy[1][2] Humoral hypercalcemia of malignancy[3][4][5][6] Tumor cells secretes parathyroid hormone-related protein (PTHrP) which has similar action as parathyroid hormone. -- ↑ ↓/Normal ↑ PTHrP

Normal/↑ calcitriol

Osteolytic tumors[7][8] Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metasteses can cause bone resorption causing hypercalcemia. ↓ ↑ -- --
Production of calcitirol[9] Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. -- ↑ -- ↑ Calcitriol
Ectopic parathyroid hormone[10] Some tumors leads to ectopic production of parathyroid hormone. ↑ ↑ ↓/Normal Normal/↑ calcitriol
Medication induced Lithium[11] Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormone and enlargement if parathyroid gland after weeks to months of therapy. ↑ ↑ -- --
Thiazide diuretics[12] Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia. -- ↑ -- -- --
Nutritional Milk-alkali syndrome Hypercalcemia is be caused by high intake of calcium carbonate. -- ↑ -- ↓ calcitriol
Vitamin D toxicity[13][14][15] Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. -- ↑ -- ↑ Vitamin D (calcidiol and/or calcitriol) --
Granulomatous disease Sarcoidosis[18] Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. -- ↑ -- ↑ Calcitriol

↑ ACE levels

References

  1. ↑ Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
  2. ↑ Stewart AF (2005). "Clinical practice. Hypercalcemia associated with cancer". N Engl J Med. 352 (4): 373–9. doi:10.1056/NEJMcp042806. PMID 15673803.
  3. ↑ Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
  4. ↑ Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
  5. ↑ Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
  6. ↑ Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE; et al. (1982). "Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity". J Clin Endocrinol Metab. 55 (2): 219–27. doi:10.1210/jcem-55-2-219. PMID 7085851.
  7. ↑ Roodman GD (2004). "Mechanisms of bone metastasis". N Engl J Med. 350 (16): 1655–64. doi:10.1056/NEJMra030831. PMID 15084698.
  8. ↑ Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF; et al. (1996). "Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis". J Clin Invest. 98 (7): 1544–9. doi:10.1172/JCI118947. PMC 507586. PMID 8833902.
  9. ↑ Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F (1994). "Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma". Ann Intern Med. 121 (9): 633–40. PMID 7944070.
  10. ↑ VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
  11. ↑ Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
  12. ↑ Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ; et al. (2016). "Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades". J Clin Endocrinol Metab. 101 (3): 1166–73. doi:10.1210/jc.2015-3964. PMC 4803175. PMID 26751196.
  13. ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
  14. ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
  15. ↑ Sharma OP (1996). "Vitamin D, calcium, and sarcoidosis". Chest. 109 (2): 535–9. PMID 8620732.
  16. ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
  17. ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
  18. ↑ Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.
Retrieved from "https://www.wikidoc.org/index.php?title=Parathyroid_adenoma_differential_diagnosis&oldid=1570072"